Press Releases Latest Apr 15, 2024 Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders Press Releases Year None202420232022202120202019201820172016201520142013 Apr 10, 2021 Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types Mar 29, 2021 Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets Mar 24, 2021 Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Mar 20, 2021 Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect On Immune Response Linked To Liver Inflammation Mar 10, 2021 Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021 Feb 25, 2021 Theratechnologies to Present at the H.C. Wainwright Global Life Sciences Conference Feb 25, 2021 Theratechnologies Announces Fourth-Quarter And Fiscal-Year 2020 Financial Results Feb 11, 2021 Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020 Feb 04, 2021 Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers Jan 19, 2021 Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option First page « Previous page ‹ … Page 9 Page 10 Page 11 Page 12 Current page 13 Page 14 Page 15 Page 16 Page 17 … Next page › Last page » Displaying 121 - 130 of 360
Apr 15, 2024 Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
Apr 10, 2021 Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types
Mar 29, 2021 Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets
Mar 24, 2021 Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors
Mar 20, 2021 Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect On Immune Response Linked To Liver Inflammation
Mar 10, 2021 Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
Feb 04, 2021 Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers
Jan 19, 2021 Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
